Nurix Therapeutics Inc (NASDAQ: NRIX) is -50.64% lower on its value in year-to-date trading and has touched a low of $8.18 and a high of $29.56 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The NRIX stock was last observed hovering at around $9.65 in the last trading session, with the day’s loss setting it -0.35%.
Currently trading at $9.30, the stock is -11.73% and -22.79% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.25 million and changing -3.58% at the moment leaves the stock -52.27% off its SMA200. NRIX registered -27.23% loss for a year compared to 6-month loss of -61.99%.
The stock witnessed a -4.32% gain in the last 1 month and extending the period to 3 months gives it a -51.56%, and is -19.34% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.88% over the week and 8.21% over the month.
Nurix Therapeutics Inc (NRIX) has around 286 employees, a market worth around $708.99M and $56.42M in sales. Profit margin for the company is -369.40%. Distance from 52-week low is 13.69% and -68.54% from its 52-week high. The company has generated returns on investments over the last 12 months (-41.61%).
The EPS is expected to shrink by -2.87% this year
The shares outstanding are 76.23M, and float is at 74.71M with Short Float at 19.26%.
The top institutional shareholder in the company is BLACKROCK INC. with over 6.82 million shares valued at $142.33 million. The investor’s holdings represent 10.9334 of the NRIX Shares outstanding. As of 2024-06-30, the second largest holder is REDMILE GROUP, LLC with 4.42 million shares valued at $92.32 million to account for 7.0917 of the shares outstanding. The other top investors are DEEP TRACK CAPITAL, LP which holds 3.99 million shares representing 6.3989 and valued at over $83.3 million, while BAKER BROS. ADVISORS LP holds 6.2236 of the shares totaling 3.88 million with a market value of $81.02 million.
Nurix Therapeutics Inc (NRIX) Insider Activity
The most recent transaction is an insider sale by van Houte Hans, the company’s Chief Financial Officer. SEC filings show that van Houte Hans sold 6,198 shares of the company’s common stock on May 02 ’25 at a price of $11.33 per share for a total of $70243.0. Following the sale, the insider now owns 33724.0 shares.
Still, SEC filings show that on Apr 30 ’25, Hansen Gwenn (Chief Scientific Officer) disposed off 3,377 shares at an average price of $11.50 for $38841.0. The insider now directly holds 61,516 shares of Nurix Therapeutics Inc (NRIX).
